The plasma NDE levels of pT181 Tau and Aβ1–42 in AD patients also do not correlate with cognitive decline [138], whereas the mean longitudinal plasma NDE levels of pT181 Tau in preclinical AD patients were associated with cognitive performance [135]. Here, MAPT is linked to Alzheimer disease.